This is all thanks to the micro RNAs that are present in the Cerebrospinal Fluid. This discovery came to light when researchers were figuring out that whether Nilotinib can reduce both the motor and non-motor symptoms that arise during Parkinson’s.
Parkinson’s disease is a neurodegenerative condition that affects the motor functions of an individual. With almost one million affected population globally Parkinson’s disease is a major threat for mankind.
For quite some time researchers have been focusing on various biomarkers which can help them to understand the progression of this disease. This disease has various common signs and symptoms but a concrete cure is still not developed for this progressive neurologic condition.
According to Dr. Moussa:
“This study shows that you can go to the microRNAs, which are the most stable chemicals in the cerebral spinal fluid, [to work out which genes are being expressed there]. And because you can detect microRNAs, then these microRNAs can be benchmarked as biomarkers of disease — not only what happens longitudinally in Parkinson’s disease, and other new diseases, but also [it] can be used as a marker of drug response.”
This first-of-its-kind research can change the way we have been treating Parkinson’s disease for the greater good.